IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3836
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$0
Oren Shuster
IM Cannabis Corp. engages in breeding, growing, and supply medical cannabis products. It offers cannabis flowers and strain specific cannabis extracts under the IMC brand; dried flower, pre-rolls, and pressed hash offerings under the WAGNERS and Highland Grow brands. The company serves medical patients and adult-use recreational consumers.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$IMCC IM Cannabis Corp. | 38 | 41 | 22 | 12 | - | - | -898.0% | -120.2% | 15.6% | -18.9% | -21.8% | - | - | 339.0x | $0 | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
IM Cannabis Corp. (IMCC) receives a "Avoid" rating with a composite score of 37.5/100. It ranks #3836 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Average quality profile
Average volatility — neutral timing signal
Moderate investment profile
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for IMCC.
View All RatingsROIC -47.9% vs WACC 16.7% (spread -64.6%)
GM 16% vs sector 44%, OM -19% vs sector 3%
Capital turnover 3.20x
Rev growth N/A, 5yr history
Interest coverage -2.3x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate IM Cannabis Corp. (IMCC) as Avoid with a composite score of 37.5/100 at a current price of $0.83. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
IM Cannabis Corp. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 37.5/100 places it at rank #3836 in our full universe.
No Moat
High
Poor
Fair Value
Stable competitive position in a defensive sector.
Leverage of 339% D/E amplifies downside risk.
Weak momentum suggests persistent institutional selling pressure.
Vulnerability to macroeconomic shocks and interest rate volatility.
IM Cannabis Corp. represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags IM Cannabis Corp. with an Avoid rating, assigning a composite score of 37.5/100 and 1 out of 5 stars. Ranked #3836 of 7,333 stocks, IMCC falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
IMCC's quality score of 41/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -898.0% (sector avg: -1.9%), gross margins of 15.6% (sector avg: 44.1%), net margins of -21.8% (sector avg: 1.0%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
IMCC registers a value score of just 22/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 1.54x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
With an investment score of 56/100, IMCC exhibits moderate growth-oriented spending. Key growth metrics include a return on assets of -120.2% (sector: 0.9%). The company appears to be balancing growth investments with capital returns, though the pace of investment may not be enough to accelerate top-line growth meaningfully.
IM Cannabis Corp. is experiencing notably weak momentum with a score of just 12/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth data is not currently available, while a beta of 0.33 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
IMCC's stability score of 40/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 0.33 and a debt-to-equity ratio of 339.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
IMCC's short interest factor score of 88/100 indicates very low short selling activity relative to peers — a positive signal suggesting institutional investors see limited near-term downside. Specific risk factors include elevated leverage (D/E: 339.00x), micro-cap liquidity risk. As a micro-cap company with a market capitalization of $0, IM Cannabis Corp. benefits from the generally lower volatility and deeper liquidity associated with its size class.
IM Cannabis Corp. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #3836 of 7,333 overall (48th percentile). Key comparisons include ROE of -898.0% trailing the -1.9% sector median and operating margins of -18.9% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While IMCC currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Momentum (12) would have the largest impact on the composite score.
ROE 47165% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 65% BELOW SECTOR MEDIAN
Op. Margin 855% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
IM Cannabis Corp. has regained compliance with Nasdaq Listing Rule 5550(b)(1), ensuring its common stock will continue to be traded on the Nasdaq Capital Market. The company, a leading medical cannabis provider in Israel and Germany, focuses on premium products and a data-driven approach to market presence and regulatory compliance. This compliance strengthens its financial standing and supports its ongoing operations and strategic initiatives.
IM Cannabis Corp. has signed a non-binding term sheet to acquire a 60% equity stake in a quantum computing bio data company for up to $54 million. This strategic diversification aims to leverage quantum computing for enhancing biological data storage, analysis, and processing. The acquisition will involve cash, shares, and performance-based earn-outs, while IM Cannabis shares currently reflect a decrease of 10.16% on the Nasdaq.
IM Cannabis (IMCC) has announced plans to sell 9.79 million common shares as part of its financial planning, allowing current shareholders to divest holdings. The company, operating in the medical cannabis sector primarily in Israel and Germany, faces significant financial challenges including negative revenue growth, profitability issues, high leverage, and a low Altman Z-Score suggesting bankruptcy risk. Despite a potentially undervalued P/S ratio, investors are advised to carefully consider the company's poor financial strength and high stock volatility.
IM Cannabis Corp. (NASDAQ:IMCC) has seen its share price drop by 26% over the last month and 38% over the past year, leading to a low price-to-sales (P/S) ratio of 0.2x. This low valuation is attributed to the company's unimpressive revenue growth, which has shown no tangible growth over the last year and only 5.2% over three years, significantly underperforming the industry's predicted 27% growth. The article suggests that shareholders are accepting the low P/S due to anticipated continued weak revenue performance.
IM Cannabis Corp. (NASDAQ:IMCC), a medical cannabis company, has appointed Alon Dayan to its board of directors, effective December 31, 2025. Dayan brings over 15 years of executive experience in homeland security technology and previously served as CEO of Virtual Crypto Technologies Inc. This appointment comes as IM Cannabis explores expansion into the U.S. cannabis market and makes other strategic moves, including evaluating a potential acquisition and appointing a new CFO.